Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
05 2019
Historique:
received: 18 10 2018
revised: 11 12 2018
accepted: 19 12 2018
pubmed: 11 2 2019
medline: 29 4 2020
entrez: 11 2 2019
Statut: ppublish

Résumé

To determine the feasibility, safety and tolerability of lumbar punctures (LPs) in research participants with early Parkinson disease (PD), subjects without evidence of dopaminergic deficiency (SWEDDs) and healthy volunteers (HC). Cerebrospinal fluid (CSF) analysis is becoming an essential part of the biomarkers discovery effort in PD with still limited data on safety and feasibility of serial LPs in PD participants. Parkinson's Progression Marker Initiative (PPMI) is a longitudinal observation study designed to identify PD progression biomarkers. All PPMI participants undergo LP at baseline, 6, 12 months and yearly thereafter. CSF collection is performed by a trained investigator using predominantly atraumatic needles. Adverse events (AEs) are monitored by phone one week after LP completion. We analyzed safety data from baseline LPs. PPMI enrolled 683 participants (423 PD/196 HC/64 SWEDDs) from 23 study sites. CSF was collected at baseline in 97.5% of participants, of whom 5.4% underwent collection under fluoroscopy. 23% participants reported any related AEs, 68% of all AE were mild while 5.6% were severe. The most common AEs were headaches (13%) and low back pain (6.5%) and both occurred more commonly in HC and SWEDDs compared to PD participants. Factors associated with higher incidence of AEs across the cohorts included female gender, younger age and use of traumatic needles with larger diameter. AEs largely did not impact compliance with the future LPs. LPs are safe and feasible in PD research participants. Specific LP techniques (needle type and gauge) may reduce the overall incidence of AEs.

Sections du résumé

OBJECTIVE
To determine the feasibility, safety and tolerability of lumbar punctures (LPs) in research participants with early Parkinson disease (PD), subjects without evidence of dopaminergic deficiency (SWEDDs) and healthy volunteers (HC).
BACKGROUND
Cerebrospinal fluid (CSF) analysis is becoming an essential part of the biomarkers discovery effort in PD with still limited data on safety and feasibility of serial LPs in PD participants.
DESIGN/METHODS
Parkinson's Progression Marker Initiative (PPMI) is a longitudinal observation study designed to identify PD progression biomarkers. All PPMI participants undergo LP at baseline, 6, 12 months and yearly thereafter. CSF collection is performed by a trained investigator using predominantly atraumatic needles. Adverse events (AEs) are monitored by phone one week after LP completion. We analyzed safety data from baseline LPs.
RESULTS
PPMI enrolled 683 participants (423 PD/196 HC/64 SWEDDs) from 23 study sites. CSF was collected at baseline in 97.5% of participants, of whom 5.4% underwent collection under fluoroscopy. 23% participants reported any related AEs, 68% of all AE were mild while 5.6% were severe. The most common AEs were headaches (13%) and low back pain (6.5%) and both occurred more commonly in HC and SWEDDs compared to PD participants. Factors associated with higher incidence of AEs across the cohorts included female gender, younger age and use of traumatic needles with larger diameter. AEs largely did not impact compliance with the future LPs.
CONCLUSIONS
LPs are safe and feasible in PD research participants. Specific LP techniques (needle type and gauge) may reduce the overall incidence of AEs.

Identifiants

pubmed: 30738748
pii: S1353-8020(18)30559-5
doi: 10.1016/j.parkreldis.2018.12.025
pmc: PMC8978879
mid: NIHMS1789422
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Multicenter Study Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

201-209

Subventions

Organisme : NINDS NIH HHS
ID : U01 NS084495
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002369
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 AG999999
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS077108
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS077352
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL091843
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS082329
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS079163
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS038529
Pays : United States

Investigateurs

Kenneth Marek (K)
Andrew Siderowf (A)
John Seibyl (J)
Christopher Coffey (C)
Caroline Tanner (C)
Duygu Tosun-Turgut (D)
Tanya Simuni (T)
Leslie Shaw (L)
John Trojanowski (J)
Andrew Singleton (A)
Karl Kieburtz (K)
Arthur Toga (A)
Brit Mollenhauer (B)
Douglas Galasko (D)
Werner Poewe (W)
Tatiana Foroud (T)
Kathleen Poston (K)
Todd Sherer (T)
Sohini Chowdhury (S)
Mark Frasier (M)
Catherine Kopil (C)
Vanessa Arnedo (V)
Kenneth Marek (K)
Nichole Daegele (N)
Cynthia Casaceli (C)
Ray Dorsey (R)
Renee Wilson (R)
Sugi Mahes (S)
John Seibyl (J)
Christina Salerno (C)
Christopher Coffey (C)
Chelsea Caspell-Garcia (C)
Arthur Toga (A)
Karen Crawford (K)
Tatiana Foroud (T)
Paola Casalin (P)
Giulia Malferrari (G)
Mali Gani Weisz (MG)
Avi Orr-Urtreger (A)
John Trojanowski (J)
Leslie Shaw (L)
Andrew Singleton (A)
Tatiana Foroud (T)
Tatiana Foroud (T)
Thomas Montine (T)
Tatiana Foroud (T)
David Russell (D)
Caroline Tanner (C)
Tanya Simuni (T)
Nabila Dahodwala (N)
Brit Mollenhauer (B)
Douglas Galasko (D)
Werner Poewe (W)
Nir Giladi (N)
Stewart Factor (S)
Penelope Hogarth (P)
David Standaert (D)
Robert Hauser (R)
Joseph Jankovic (J)
Marie Saint-Hilaire (M)
Irene Richard (I)
David Shprecher (D)
Hubert Fernandez (H)
Katrina Brockmann (K)
Liana Rosenthal (L)
Paolo Barone (P)
Alberto Espay (A)
Dominic Rowe (D)
Karen Marder (K)
Anthony Santiago (A)
Susan Bressman (S)
Shu-Ching Hu (SC)
Stuart Isaacson (S)
Jean-Christophe Corvol (JC)
Javiar Ruiz Martinez (JR)
Eduardo Tolosa (E)
Yen Tai (Y)
Marios Politis (M)
Debra Smejdir (D)
Linda Rees (L)
Karen Williams (K)
Farah Kausar (F)
Karen Williams (K)
Whitney Richardson (W)
Diana Willeke (D)
Shawnees Peacock (S)
Beatrice Heim (B)
Anat Mirelman (A)
Barbara Sommerfeld (B)
Alison Freed (A)
Katrina Wakeman (K)
Courtney Blair (C)
Stephanie Guthrie (S)
Leigh Harrell (L)
Christine Hunter (C)
Cathi-Ann Thomas (CA)
Raymond James (R)
Grace Zimmerman (G)
Victoria Brown (V)
Jennifer Mule (J)
Ella Hilt (E)
Kori Ribb (K)
Susan Ainscough (S)
Misty Wethington (M)
Madelaine Ranola (M)
Helen Mejia Santana (HM)
Juliana Moreno (J)
Deborah Raymond (D)
Krista Speketer (K)
Lisbeth Carvajal (L)
Stephanie Carvalho (S)
Ioana Croitoru (I)
Alicia Garrido (A)
Laura Marie Payne (LM)
Veena Viswanth (V)
Lawrence Severt (L)
Maurizio Facheris (M)
Holly Soares (H)
Mark A Mintun (MA)
Jesse Cedarbaum (J)
Peggy Taylor (P)
Kevin Biglan (K)
Emily Vandenbroucke (E)
Zulfiqar Haider Sheikh (ZH)
Baris Bingol (B)
Tanya Fischer (T)
Pablo Sardi (P)
Remi Forrat (R)
Alastair Reith (A)
Jan Egebjerg (J)
Gabrielle Ahlberg Hillert (GA)
Barbara Saba (B)
Chris Min (C)
Robert Umek (R)
Joe Mather (J)
Susan De Santi (S)
Anke Post (A)
Frank Boess (F)
Kirsten Taylor (K)
Igor Grachev (I)
Andreja Avbersek (A)
Pierandrea Muglia (P)
Kaplana Merchant (K)
Johannes Tauscher (J)

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

J Alzheimers Dis. 2014;39(4):719-26
pubmed: 24254700
Cochrane Database Syst Rev. 2017 Apr 07;4:CD010807
pubmed: 28388808
Spine J. 2015 Jan 1;15(1):115-21
pubmed: 25041726
Alzheimer Dis Assoc Disord. 2017 Oct-Dec;31(4):287-294
pubmed: 28891819
Lancet. 2018 Mar 24;391(10126):1197-1204
pubmed: 29223694
Curr Alzheimer Res. 2009 Jun;6(3):290-2
pubmed: 19519311
Mov Disord. 2018 May;33(5):771-782
pubmed: 29572948
Alzheimer Dis Assoc Disord. 2005 Oct-Dec;19(4):220-5
pubmed: 16327349
Mov Disord Clin Pract. 2016 Jul 18;3(6):538-547
pubmed: 30363567
Alzheimers Dement. 2016 Feb;12(2):154-163
pubmed: 26368321
Front Aging Neurosci. 2014 Apr 09;6:65
pubmed: 24782762
J Clin Neurosci. 2014 Mar;21(3):536-7
pubmed: 24156907
Neurology. 2002 Dec 24;59(12):2008-9
pubmed: 12499507

Auteurs

Neha Prakash (N)

Northwestern University Feinberg School of Medicine, USA. Electronic address: neha.prakash@northwestern.edu.

Chelsea Caspell-Garcia (C)

The University of Iowa, USA. Electronic address: chelsea-caspell@uiowa.edu.

Christopher Coffey (C)

The University of Iowa, USA. Electronic address: christopher-coffey@uiowa.edu.

Andrew Siderowf (A)

The University of Pennsylvania, USA. Electronic address: Andrew.siderowf@uphs.upenn.edu.

Caroline M Tanner (CM)

University of California San Francisco, USA. Electronic address: caroline.tanner@ucsf.edu.

Karl Kieburtz (K)

University of Rochester Medical Center, USA. Electronic address: karl.kieburtz@chet.rochester.edu.

Brit Mollenhauer (B)

Center of Parkinsonism and Movement Disorders Paracelsus-Elena Klinik Kassel and University Medical Center Goettingen, Germany. Electronic address: brit.mollenhauer@med.uni-goettingen.de.

Douglas Galasko (D)

University of California San Diego, USA. Electronic address: dgalasko@ucsd.edu.

Kalpana Merchant (K)

TransThera Consulting, USA. Electronic address: merchant.transthera@gmail.com.

Tatiana Foroud (T)

Indiana University, USA. Electronic address: tforoud@iu.edu.

Lana M Chahine (LM)

University of Pittsburgh, USA. Electronic address: lanachahine@pitt.edu.

Daniel Weintraub (D)

The University of Pennsylvania, USA. Electronic address: daniel.weintraub@uphs.penn.edu.

Cindy Casaceli (C)

University of Rochester Medical Center, USA. Electronic address: cindy.casaceli@chet.rochester.edu.

Ray Dorsey (R)

University of Rochester Medical Center, USA. Electronic address: ray.dorsey@chet.rochester.edu.

Renee Wilson (R)

Clinical Trial Coordination Center, University of Rochester Medical Center, USA. Electronic address: renee.wilson@chet.rochester.edu.

Margaret Herzog (M)

Michael J Fox Foundation, USA.

Nichole Daegele (N)

Institute for Neurodegenerative Disorders, USA. Electronic address: ndaegele@invicro.com.

Vanessa Arnedo (V)

Michael J Fox Foundation, USA. Electronic address: varnedo@michaeljfox.org.

Mark Frasier (M)

Michael J Fox Foundation, USA. Electronic address: mfrasier@michaeljfox.org.

Todd Sherer (T)

Michael J Fox Foundation, USA. Electronic address: tsherer@michaeljfox.org.

Ken Marek (K)

Institute for Neurodegenerative Disorders, USA. Electronic address: kmarek@mnimaging.com.

Samuel Frank (S)

Harvard Medical School, Beth Israel Deaconess Medical Center, Parkinson's Disease and Movement Disorders Center, Director of the HDSA Center of Excellence, USA. Electronic address: sfrank2@bidmc.harvard.edu.

Danna Jennings (D)

Denali Therapeutics, USA. Electronic address: jennings@dnli.com.

Tanya Simuni (T)

Northwestern University Feinberg School of Medicine, USA. Electronic address: tsimuni@nmff.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH